A Multi-Dose Study to Assess Tolerability, Safety and Pharmacology of hGH-ViaDerm™ System in Adults With GH-Deficiency
NCT ID: NCT00455260
Last Updated: 2013-09-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
60 participants
INTERVENTIONAL
2007-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
hGH-ViaDerm™ System (hGH or somatropin)
transdermal patch; Group 1: 0.2 mg/day SC hGH during Period I, and 0.5 mg per transdermal patch during Period III (expected equivalent dose to SC 0.2 mg/day) Group 2: 0.4 mg/day SC hGH during Period I, and 2.0 mg per transdermal patch during Period III (expected equivalent dose to SC 0.4 mg/day) Group 3: 1.0 mg/day SC hGH during Period I, and 5.0 mg per transdermal patch during Period III (expected equivalent dose to 1.0 mg/day)
hGH-ViaDerm™ System
The hGH-ViaDerm™ System is a transdermal delivery system for somatropin (hGH, rDNA origin).
The ViaDerm System™ consists of a medical device component and a printed dry hGH patch component. The device component is comprised of two primary elements: a reusable, computer mouse-like electronic controller and a disposable sterile array, which is inserted onto the base of the controller, delivers RF-current to ablate cells and creates microscopic throughways, termed RF-MicroChannels™, across the stratum corneum into the upper epidermis. The drug component consists of a unique circular transdermal dry hGH patch formulated specifically for use with the ViaDerm™ device. hGH is delivered by passive diffusion through the RF-MicroChannels™ into the systemic circulation system.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Clinical diagnosis of Adult Growth Hormone Deficiency (AGHD) meeting one of the following criteria:
* Three or more additional pituitary hormone deficiencies, based on well documented medical history from up to 10 years prior to screening, and/or serum IGF-1 levels below 2 SD from normal level, measured up to 4 months prior to screening.
* One or two additional pituitary hormone deficiencies with one GH stimulating test performed within 10 years prior to screening: Insulin Tolerance test with GH levels less than 5.1 µg/L or ARG-GHRH with GH levels less than 4.1 µg/L.
* Isolated GH deficient subjects with two well-documented GH stimulating tests performed within 10 years prior to screening. Insulin Tolerance test with GH levels less than 5.1 µg/L or ARG-GHRH with GH levels less than 4.1 µg/L.
* In childhood onset AGHD, confirmation of GHD following attainment of full height.
2. Subjects using hormone replacement therapy for additional pituitary deficits must be on an optimized treatment regimen for at least three months prior to screening.
3. Willing and able to provide written informed consent prior to performing any study procedures.
Exclusion Criteria
2. For female subjects: pregnancy or lactation or use of oral contraception or unacceptable method of contraception throughout the study.
3. Active acromegaly in the last 5 years.
4. Carpal tunnel syndrome.
5. Prader-Willi syndrome.
6. Active Cushing's syndrome within the last 12 months.
7. Non-compliance for upper arm SC injection or patch application.
8. Skin color or tattoo that would not enable detection of erythema.
9. Upper extremities with skin marks, bruises, cuts, abrasions on the upper arm.
10. Dense and dark hair growth on upper extremities.
11. History of skin hypersensitivity and/or allergies.
12. Known hypersensitivity to somatropin or mannitol
13. Evidence of active malignancy.
14. Previous use of chemotherapy, immunosuppressive or radiation therapy, except for treatment of pituitary disease.
15. Serum glucose (fasting) \> 126 mg/dl.
16. Known or suspected HIV-positive subjects or subjects with advanced diseases such as AIDS, Hepatitis C, Hepatitis B or tuberculosis.
17. Subjects who, based on the investigator's judgment, have a clinically significant or unstable medical or surgical condition that may preclude safe and complete study participation. Conditions may include cardiovascular, vascular, pulmonary, hepatic, renal, or neurological disease, as determined by medical history, physical examination, laboratory tests or ECG.
18. BMI \< 19 and ≥ 35 kg/m2.
19. Weight reducing drugs or appetite suppressants.
20. Estrogen replacement therapy except transdermal patch.
21. Any psychological condition which may influence the compliance with the study requirements.
22. Unstabilized antidepressant or antipsychotic medication therapy within 2 months prior to screening.
23. Subjects with a known history of alcohol abuse.
24. Subjects who received blood or plasma derivatives in the three months preceding screening.
25. Subjects who donated blood in the preceding three months of screening or intend to make a blood donation during the study, or within the three months following the study completion.
26. Subjects who have participated in another clinical study of any kind (drug or device) in the one month prior to screening.
27. Subjects who, in the judgment of the investigator, are likely to be non-compliant or uncooperative during the study.
20 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Teva Branded Pharmaceutical Products R&D, Inc.
INDUSTRY
TransPharma Medical
INDUSTRY
Teva Neuroscience, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Noa Avisar, PhD
Role: STUDY_DIRECTOR
Teva Branded Pharmaceutical Products R&D, Inc.
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GH-VD-102
Identifier Type: -
Identifier Source: org_study_id